medigraphic.com
Revista Médica Sinergia

2023, Number 02

<< Back

Revista Médica Sinergia 2023; 8 (02)

Overview of atypical parkinsonisms

Castro FM, Gamboa MS, Guevara SMF

Language: Spanish
References: 17
Page:
PDF size: 152.28 Kb.


ABSTRACT

There's a group of relentlessly progressive pathologies classified as atypical parkinsonisms, this group includes progressive supranuclear palsy (PSP), multiple system atrophy (MSA), corticobasal degeneration (CBD) and frontotemporal lobar degeneration (FTLD). Making a diagnosis can be complex even for neurologists due to a growing recognized phenotypic variability, multifactorial etiology, and clinical heterogeneity. The diagnosis of these pathologies is mainly based on the clinical features of each disease and in radiologic imaging techniques. There's still much research to be made regarding etiology, diagnostic accuracy and treatment to hopefully better the quality of life for these patients.


REFERENCES

  1. Shrimanker I, Tadi P, Sánchez-Manso JC.Parkinsonism. 2022, Jun 07. In: StatPearls[Internet]. Treasure Island (FL): StatPearlsPublishing; 2022, Jan. PMID: 31194381.Disponible en:https://pubmed.ncbi.nlm.nih.gov/31194381/

  2. Fahn S. The 200-year journey of Parkinsondisease: Reflecting on the past and lookingtowards the future. Parkinsonism Relat Disord.2018 Jan;46 Suppl 1:S1-S5. DOI:10.1016/j.parkreldis.2017.07.020. Epub 2017 Aug1. PMID: 28784297. Disponible en:https://pubmed.ncbi.nlm.nih.gov/28784297/

  3. Deutschländer AB, Ross OA, Dickson DW,Wszolek ZK. Atypical parkinsonian syndromes: ageneral neurologist's perspective. Eur J Neurol.2018, Jan;25(1):41-58. DOI: 10.1111/ene.13412.Disponible en:https://pubmed.ncbi.nlm.nih.gov/28803444/

  4. Aludin S, Schmill LA. MRI Signs of Parkinson'sDisease and Atypical Parkinsonism. Rofo. 2021,Dec;193(12):1403-1410. English, German. DOI:10.1055/a-1460-8795. Disponible en:https://pubmed.ncbi.nlm.nih.gov/34034347/

  5. Fanciulli A, Stankovic I, Krismer F, Seppi K, LevinJ, Wenning GK. Multiple system atrophy. Int RevNeurobiol. 2019;149:137-192. DOI:10.1016/bs.irn.2019.10.004. Disponible en:https://pubmed.ncbi.nlm.nih.gov/31779811/

  6. Friedberg A, Erikh I, Nassar M, Sprecher E,Schlesinger I. Efficacy of Parenteral AmantadineTherapy in the Treatment of Multiple SystemAtrophy with Predominant Parkinsonism. ClinNeuropharmacol. 2018, Sep-Oct;41(5):160-163.DOI: 10.1097/WNF.0000000000000291.Disponible en:https://pubmed.ncbi.nlm.nih.gov/30024441/

  7. Agarwal S, Gilbert R. Progressive SupranuclearPalsy. 2022, Apr 3. In: StatPearls [Internet].Treasure Island (FL): StatPearls Publishing; 2022,Jan. PMID: 30252354. Disponible en:https://pubmed.ncbi.nlm.nih.gov/30252354/

  8. Krzosek P, Madetko N, Migda A, Migda B, JaguśD, Alster P. Differential Diagnosis of Rare Subtypesof Progressive Supranuclear Palsy and PSP-LikeSyndromes-Infrequent Manifestations of the MostCommon Form of Atypical Parkinsonism. FrontAging Neurosci. 2022, Feb 09;14:804385. DOI:10.3389/fnagi.2022.804385. Disponible en:https://www.frontiersin.org/articles/10.3389/fnagi.2022.804385/full

  9. Saranza GM, Whitwell JL, Kovacs GG, Lang AE.Corticobasal degeneration. Int Rev Neurobiol.2019;149:87-136. DOI:

  10. 10.1016/bs.irn.2019.10.014. Disponible en:https://pubmed.ncbi.nlm.nih.gov/31779825/10. Constantinides VC, Paraskevas GP, ParaskevasPG, Stefanis L, Kapaki E. Corticobasaldegeneration and corticobasal syndrome: Areview. Clin Park Relat Disord. 2019, Aug 30;1:66-71. DOI: 10.1016/j.prdoa.2019.08.005. Disponibleen:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8288513/

  11. Svenningsson P. Corticobasal degeneration:advances in clinicopathology and biomarkers. CurrOpin Neurol. 2019 Aug;32(4):597-603. DOI:10.1097/WCO.0000000000000707. Disponible en:https://pubmed.ncbi.nlm.nih.gov/31145128/

  12. Mann DMA, Snowden JS. Frontotemporal lobardegeneration: Pathogenesis, pathology andpathways to phenotype. Brain Pathol. 2017,Nov;27(6):723-736. DOI: 10.1111/bpa.12486.Disponible en:https://pubmed.ncbi.nlm.nih.gov/28100023/

  13. Banovac I, Sedmak D, Judaš M, Petanjek Z. VonEconomo Neurons - Primate-Specific orCommonplace in the Mammalian Brain? FrontNeural Circuits. 2021, Sep 01;15:714611. DOI:10.3389/fncir.2021.714611. Disponible en:https://pubmed.ncbi.nlm.nih.gov/34539353/

  14. Puppala GK, Gorthi SP, Chandran V, GundaboluG. Frontotemporal Dementia - Current Concepts.Neurol India. 2021, Sep-Oct;69(5):1144-1152.DOI: 10.4103/0028-3886.329593. Disponible en:https://pubmed.ncbi.nlm.nih.gov/34747778/

  15. Kobayashi Z, Arai T, Kawakami I, Yokota O,Hosokawa M, Oshima K, Niizato K, Shiraishi A,Akiyama H, Mizusawa H. Clinical features of thebehavioural variant of frontotemporal dementia thatare useful for predicting underlying pathologicalsubtypes of frontotemporal lobar degeneration.Psychogeriatrics. 2018, Jul;18(4):307-312. DOI:10.1111/psyg.12334. Disponible enhttps://onlinelibrary.wiley.com/doi/10.1111/psyg.12334

  16. Giunta M, Solje E, Gardoni F, Borroni B, BenussiA. Experimental Disease-Modifying Agents forFrontotemporal Lobar Degeneration. J ExpPharmacol. 2021, Mar 24;13:359-376. DOI:10.2147/JEP.S262352. Disponible en:https://pubmed.ncbi.nlm.nih.gov/33790662/

  17. Liu MN, Lau CI, Lin CP. Precision Medicine forFrontotemporal Dementia. Front Psychiatry. 2019,Feb 21;10:75. DOI: 10.3389/fpsyt.2019.00075.Disponible en:https://pubmed.ncbi.nlm.nih.gov/30846947/




2020     |     www.medigraphic.com